China-based Shanghai Henlius Biotech Inc (2696.HK) and Accord Healthcare Limited, a subsidiary of Intas Pharmaceuticals Ltd, have received approval from the European Commission (EC) for their Zercepac, a biosimilar, trastuzumab, intended for the treatment of certain patients with HER2-positive early breast cancer, HER2-positive metastatic breast cancer and earlier untreated HER2-positive metastatic gastric cancer, it was reported on Wednesday.
The product received approval based on a series of studies including comparative quality studies, preclinical and clinical studies.
Zercepac was developed and produced by Henlius and is the first monoclonal antibody (mAb) and third biosimilar, launched by Accord in Europe, and is the first mAb developed by Henlius to be approved in the European Union.
Renalytix advances kidneyintelX.Dkd scale-up with laboratory expansion and CE submission
FDA extends review timeline for Sanofi's Sarclisa subcutaneous formulation in multiple myeloma
FDA expands approval of Sanofi's Tzield for early-stage type 1 diabetes in young children
Inhibrx provides clinical update on ozekibart (INBRX-109) for colorectal cancer treatment
LENZ Therapeutics advances VIZZ regulatory expansion with UK submission for presbyopia treatment
Lundbeck presents new real-world data on VYEPTI (eptinezumab) at AAN 2026
European Commission approves Merck's ENFLONSIA for infant RSV prevention in Europe